A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 716 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Opinion: ‘We need to increase testing in primary care’ February 24, 2021 Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Load more HOT NEWS For Some Kids with Brain Cancer, Targeted Therapy is Better than... Off Target: Investigating the Abscopal Effect as a Treatment for Cancer Searching for novel connections in cancer metabolism Zucchini everywhere
